[Role of the Rho/Rho-kinase pathway in the development of hypertensive glomerulosclerosis: renoprotective effect of Rho-kinase inhibitor in hypertensive glomerulosclerosis and its molecular mechanism].
Nishikimi
Toshio
T
nishikim@dokkyomed.ac.jp
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D004195:Disease Models, Animal; D005923:Glomerulosclerosis, Focal Segmental / Q000209:etiology*; D006801:Humans; D006973:Hypertension / Q000209:etiology* / Q000628:therapy*; D047908:Intracellular Signaling Peptides and Proteins / Q000037:antagonists & inhibitors* / Q000502:physiology*; D010597:Pharmacogenetics; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology*; D051381:Rats; D020303:Rats, Inbred Dahl; D011918:Rats, Inbred SHR; D054460:rho-Associated Kinases
D047908:Intracellular Signaling Peptides and Proteins; D047428:Protein Kinase Inhibitors; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D017346:Protein Serine-Threonine Kinases; D054460:rho-Associated Kinases; C049347:fasudil